HemoGenyx Pharmaceuticals (LSE:HEMO)
A definitive Manufacturing deal with Estonia's Cellin Technologies marks a concrete step toward early Revenue for HemoGenyx's CAR-T leukaemia therapy, yet the HEMO share price fell in the days after the announcement as investors weighed execution and funding risk.
What happened
HemoGenyx Pharmaceuticals (LSE:HEMO), the London-listed clinical-stage biotech developing cell and gene therapies for blood cancers, has signed a definitive five-year deal with Cellin Technologies OÜ, a Tallinn-based cell-therapy manufacturer, to produce and commercialise its lead CAR-T candidate, HG-CT-1, in Estonia under the country's hospital exemption framework.
The deal, announced 11 August 2026, converts a letter of intent signed less than a year earlier into a binding agreement, giving HemoGenyx a route to patient revenue from HG-CT-1 in relapsed or refractory acute myeloid leukaemia (AML) ahead of full Marketing authorisation, since hospital exemption rules let bespoke cell therapies be manufactured and administered locally without the usual pan-European approval process.
Despite the milestone, HEMO shares were trading around 630.5p on 12 August 2026, down 3.74% on the day, valuing the company at roughly £42.9 million. There is no clear single-cause link between the Cellin news and the move; small-cap biotechs often see 'sell the news' reactions, and the fall should be read against dilution concerns and thin Liquidity rather than the announcement alone.
For a pre-revenue biotech that has raised Capital repeatedly over the past two years, the Estonia deal is nonetheless a rare tangible commercial catalyst — a bridge to cash generation while HG-CT-1 continues through formal Phase 1 trials in the US and UK.
Latest company news
The Cellin agreement appoints it as HemoGenyx's exclusive manufacturing partner for HG-CT-1 in Estonia for five years. Tech transfer should take about four months; HemoGenyx keeps full IP ownership, sharing net Operating Margin per patient after direct costs, with no minimum revenue guarantees. CEO Dr Vladislav Sandler said the deal 'transforms our plans' from intent to execution.
This followed a 29 July 2026 letter of intent with Vilnius University Hospital's National Cancer Centre in Lithuania, covering FLT3-positive AML/MDS research and a plan to administer HG-CT-1 under Lithuania's hospital exemption scheme. That update confirmed the core US/UK Phase 1 trial was continuing, with a second, higher adult dose cohort under way and the first paediatric patient identified for screening.
Earlier in 2026, HemoGenyx completed a manufacturing tech transfer to Made Scientific and submitted comparability data to the FDA (31 March), then filed its Annual IND Report (14 April). It held its AGM (results 1 July) and granted new share Options — 1,200,000 to directors, 60,000 to employees at £8 — with a warrant-term extension (29 May); options and warrants combined now equal roughly 20.7% of issued share capital, an overhang for shareholders.
Financial position
HemoGenyx remains pre-revenue and cash-burning. Final results for 2025 (published 30 April 2026) showed an operating loss of £9.77 million, up from £5.63 million, with cash used in operations rising to £5.82 million from £4.14 million. A further £2.29 million fair-value loss on derivative instruments added to the reported loss.
Cash at 31 December 2025 stood at £1.59 million, up from just £0.16 million a year earlier, after the company raised roughly £5.5 million of Equity during 2025 through placings, convertible Loan notes and Warrant exercises. Directors cited a 'reasonable expectation' of adequate resources for the foreseeable future, though frequent, small raises underline dependence on market access.
Post year-end, HemoGenyx raised a further £2.5 million and then £3 million via an institutional fundraise (28 April 2026), pricing 374,532 new shares at £8.01 each, earmarked to accelerate the Phase 1 trials. Shares in issue rose from roughly 4.6 million in mid-2025 to nearly 6.8 million after that raise; combined with the options/warrant pool, further dilution looks likely as the company funds scale-up ahead of revenue.
Why the shares may be under pressure
No single disclosed Factor explains the recent softness in HemoGenyx shares, and investors should be wary of assuming the Cellin deal itself triggered selling — the stock could equally be reacting to profit-taking or broader small-cap biotech sentiment.
Still, plausible contributors include a widening annual cash burn (operating loss nearly doubled year-on-year), no product revenue, and a history of raising capital in small, frequent tranches — a pattern that tends to weigh on small-cap valuations as investors price in future dilution. The options/warrant pool, over a fifth of issued capital, is a persistent overhang, and the hospital exemption route carries no guaranteed patient volumes or revenue. Thin liquidity in a roughly £43 million market-cap stock can also amplify percentage moves on modest volumes.
Bull case
The Cellin and Vilnius agreements give HemoGenyx two potential near-term revenue pathways via hospital exemption frameworks, ahead of conventional marketing authorisation — a route some cell-therapy peers have used to generate early Cash Flow and real-world data simultaneously.
HemoGenyx retains full IP ownership under both deals, preserving HG-CT-1's option value in larger markets. The Phase 1 trial is progressing, with dose escalation in adults and first steps into paediatric AML, a high-unmet-need population. FDA comparability data and the completed tech transfer to Made Scientific also de-risk the Supply chain ahead of commercial scale-up.
A definitive, binding contract — rather than a non-binding letter of intent — with a functioning GMP manufacturer in the EU gives management a credible execution narrative when raising further capital, potentially at improved terms.
Bear case
HemoGenyx is still years, at best, from sustainable revenue, and the hospital exemption agreements carry no minimum patient or revenue guarantees, so near-term cash generation from Estonia or Lithuania could be slow to materialise.
Cash burn is accelerating (operating loss up roughly 74% year-on-year in 2025) and the company continues to rely on repeated equity and convertible-instrument raises, each risking further dilution — underscored by the sizeable options and warrant pool.
Clinical execution risk remains central: AML is a difficult indication, CAR-T manufacturing and delivery logistics are complex, and there is no guarantee the Phase 1 trial produces data supportive of further development or approval. As a small, Illiquid biotech, HEMO shares can also be volatile on low volumes.
What investors should watch next
Near-term catalysts include further Phase 1 dose-escalation data in adults, initial paediatric progress, updates on the Cellin tech transfer (due roughly four months after the 11 August signing), and news on the Lithuania workstream.
Investors should also monitor half-year results (six months to 30 June, expected around September 2026) for updated cash and burn rate, plus any further fundraising, warrant exercises, or changes to the options pool.
Longer term, progress on the CDX bispecific antibody and CBR platform programmes, further hospital-exemption partnerships elsewhere in Europe, and eventual regulatory filings for HG-CT-1 will indicate whether the pipeline strategy is gaining traction.
Conclusion and outlook
HemoGenyx's definitive agreement with Cellin Technologies is a genuine step forward in its strategy of using hospital exemption frameworks to generate early commercial traction for HG-CT-1, following a similar move into Lithuania weeks earlier. That the HEMO share price fell in the immediate aftermath is not necessarily a verdict on the deal — small-cap biotech stocks often trade on liquidity and sentiment as much as on individual newsflow.
The fundamental picture is familiar for clinical-stage biotechs: a widening cash burn, dependence on further raises, and a valuation hinging on execution not yet proven at scale. Investors weighing the stock will need to balance the optionality from the Estonia and Lithuania deals against funding needs and the risks of early-stage cell therapy development. This article is for information purposes only and does not constitute Investment advice.



_11_18_2026_06_43_20_247880.jpg)


Please wait processing your request...